Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Equities research analysts at Oppenheimer raised their Q1 2018 earnings per share estimates for Syros Pharmaceuticals in a report released on Monday, according to Zacks Investment Research. Oppenheimer analyst L. Cann now anticipates that the company will earn ($0.59) per share for the quarter, up from their prior estimate of ($0.88). Oppenheimer has a “Buy” rating and a $28.00 price target on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ Q2 2018 earnings at ($0.72) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($2.83) EPS, FY2019 earnings at ($2.12) EPS, FY2020 earnings at ($0.19) EPS and FY2021 earnings at $1.70 EPS.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.53).
Syros Pharmaceuticals (NASDAQ SYRS) opened at $10.80 on Thursday. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38. The stock has a market cap of $276.90, a price-to-earnings ratio of -5.37 and a beta of -3.32.
Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Syros Pharmaceuticals by 11.9% in the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after purchasing an additional 418,061 shares in the last quarter. Redmile Group LLC increased its holdings in shares of Syros Pharmaceuticals by 2.2% in the 2nd quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after purchasing an additional 20,520 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after purchasing an additional 250,507 shares in the last quarter. State Street Corp increased its holdings in shares of Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after purchasing an additional 108,250 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Syros Pharmaceuticals by 15.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 126,530 shares of the company’s stock valued at $1,926,000 after purchasing an additional 17,330 shares in the last quarter. Institutional investors own 57.96% of the company’s stock.
In other news, insider Jeremy P. Springhorn bought 15,000 shares of Syros Pharmaceuticals stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $9.08 per share, for a total transaction of $136,200.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju bought 109,774 shares of Syros Pharmaceuticals stock in a transaction dated Thursday, December 14th. The stock was purchased at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/01/20/brokers-offer-predictions-for-syros-pharmaceuticals-incs-q1-2018-earnings-syrs.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.